Acrux Limited (ARUXF) Shareholder/Analyst Call October 12, 2026 12:00 AM EDT
Company Participants
John Warmbrunn – MD, CEO & Director
Jolanta Airey – Chief Medical Officer
Felicia Colagrande – Product Development & Technical Affairs Director
Conference Call Participants
Julia Maguire
Presentation
Julia Maguire
Welcome to the Acrux Limited Investor Webinar. The ticker code is ACR. Today, we’ll run through a short presentation, and we have a video, and then we’ll open the floor to questions. [Operator Instructions]
I will now pass the floor to the team of Acrux to walk you through the presentation. Over to you.
John Warmbrunn
MD, CEO & Director
Thank you, Julia, and good afternoon, everybody. I’ll just introduce you to 2 of my colleagues. We have our Chief Medical Officer, Jolanta Airey on my right. And on my left, we have Felicia Colagrande, who’s the Product Development and Technical Affairs Director. And the reason I’ve got them here today is we’re talking about our discussions in different forms with the FDA. And I thought it would be good to get a bit of breadth of feedback from the different discussions we’ve had.
So the usual disclaimers. What we’re here to talk about today though is HSDD. And if I was to put this into common language, I guess, low libido is probably the best way to describe it in common language. But it’s really more than just low sexual desire. It has a big impact on different aspects of an individual women’s life. And it’s something that’s very common. 10% of the population are actually impacted women’s population are impacted by it. So it matters. But it actually goes beyond just the impact on the individual. It flows well beyond that into general wellness and interactions with other people. So this is something where there isn’t a therapy that needs addressing. And our story today is about Acrux’s journey